CF101 + Placebo

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 17/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uveitis, Posterior

Conditions

Uveitis, Posterior, Uveitis, Intermediate

Trial Timeline

Jan 1, 2019 → Oct 1, 2019

NCT ID

NCT01905124

About CF101 + Placebo

CF101 + Placebo is a phase 2 stage product being developed by Can Fite Biopharma for Uveitis, Posterior. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01905124. Target conditions include Uveitis, Posterior, Uveitis, Intermediate.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis, Posterior were approved

Approved (3) Terminated (8) Active (9)

🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3

🔄Baricitinib + AdalimumabEli LillyPhase 3

✅Ixekizumab Prefilled SyringeEli LillyApproved

🔄adalimumabAbbViePhase 3

🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

✅AdalimumabAbbVieApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01905124	Phase 2	Withdrawn	Jan 1, 2019	Oct 1, 2019	Uveitis, Posterior
NCT00837291	Phase 2	Withdrawn	Nov 1, 2018	Jan 1, 2019	Osteoarthritis of the Knee
NCT01265667	Phase 2/3	Completed	Jul 1, 2011	May 1, 2015	Plaque Psoriasis
NCT00556894	Phase 2	Completed	Feb 1, 2008	Apr 1, 2009	Rheumatoid Arthritis
NCT00349466	Phase 2	Completed	Jan 1, 2007	May 1, 2009	Keratoconjunctivitis Sicca

Competing Products

20 competing products in Uveitis, Posterior

See all competitors

Product	Company	Stage	Hype Score
triamcinolone acetonide (Triesence®)	Clearside Biomedical	Phase 1/2	22
4 mg CLS-TA Suprachoriodal Injection	Clearside Biomedical	Phase 3	30
Baricitinib + Adalimumab	Eli Lilly	Phase 3	44
Ixekizumab Prefilled Syringe	Eli Lilly	Approved	39
adalimumab	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab	AbbVie	Approved	43
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
AIN457	Novartis	Phase 3	32
Myfortic	Novartis	Pre-clinical	22
AIN457 + AIN457 + Placebo AIN457	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
Ranibizumab	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AEB071	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
Myfortic + Decortin	Novartis	Phase 3	40
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35